Profound Medical Corp.
Close on Oct 19, 2026
- Market cap
- $213.01M
- P/E (TTM)
- 4.2
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $2.50M | $-0.26 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $5.30M | $-0.19 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | After market close | $6.00M | $-0.27 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 7, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | $2.20M | $-0.52 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $2.60M | $-0.36 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 8, 2025 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| gross margin | full year 2026 | 70% | Maintained |
| total revenue | full-year 2026 | $25.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Profound Medical filed with the SEC
TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
Results of operations · EX-99.1 to Form 8-K
Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Profound’s Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days’
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical Announces Management Change
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Robotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN Trial
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound to Showcase TULSA-PRO®, the TULSA Procedure and the Future of iMRI at AUA2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical Reports Strong First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure Milestone
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure for Prostate Disease
Regulation FD disclosure · EX-99.1 to Form 8-K
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical Announces Upcoming Investor Events
Regulation FD disclosure · EX-99.1 to Form 8-K
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Surpasses 2025 TULSA-PRO® Installed Base Goal
Regulation FD disclosure · EX-99.1 to Form 8-K
Hopkins Medicine Treats First Commercial TULSA-PRO® Case
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical Corp. Announces Closing of
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical Corp. Announces Pricing of
Material agreement · Other events · EX-99.1 to Form 8-K
Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter
Results of operations · EX-99.1 to Form 8-K
Profound Medical Announces Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Famed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For TULSA-PRO®
Regulation FD disclosure · EX-99.1 to Form 8-K
Profound Medical Announces First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Established & Increasing Clinical Evidence Continue to Validate TULSA Review of all prostate ultrasound (and IRE) ablation publications from the U.S.
Regulation FD disclosure · EX-99.1 to Form 8-K